

Date: July 14, 2025

To

National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (East),
Mumbai – 400 051

Dear Sir/Madam,

Subject: Financial results for the quarter ended March 31, 2025

This is to inform that due to an inadvertent error in scanning, the signature page of the Auditor's Report submitted earlier for the quarter and year ended March 31, 2025, was unclear. Accordingly, a clear scanned copy of the complete set of the audited standalone and consolidated financial results is being uploaded on the stock exchange portal.

We confirm that there are no changes in the figures of the audited standalone and consolidated financial results and the Auditor's Report as compared to the version previously submitted.

We kindly request you to take the above on record.

For OneSource Specialty Pharma Limited

Trisha A 
Digitally signed by
Trisha A
Date: 2025.07.14
19:22:09 +05'30'

Trisha A
Company Secretary and Compliance officer
Membership No. A47635

Date: May 05, 2025

BSE Limited Listing Department- Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001 Scrip Code: 544292, ISIN: INE013P01021	National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051 Symbol: ONESOURCE
---	---

Dear Sir/ Madam,

Subject: **Intimation under Regulation 30 and 51(2) read with Schedule III, Part B of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015**

Pursuant to Regulation 30 and 51(2) read with Schedule III, Part A and Part B of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, (herein referred as LODR), we hereby inform you that, the Board of directors at its meeting held today, Monday, May 05, 2025 i.e., which commenced at 15:45 hrs (IST) and concluded at 19:15 hrs (IST), inter alia approved the following items:

1. Audited Financial Results (Standalone and Consolidated) of the Company for quarter and year ended March 31, 2025.

A copy of the Audited Financial Results (Standalone and Consolidated) for quarter and year ended March 31, 2025, along with Auditors' Report has been enclosed herewith;

2. Appointment of M/s. D V & Associates as Secretarial Auditor of the Company for a term of 5 (five) years.
3. In-principle approval to consolidate the Singapore business operations of its wholly owned subsidiary, Stelis Pte Ltd, and/or its wholly owned step-down subsidiary, Strides Softgel Pte Ltd, into another wholly owned subsidiary, Onesource Specialty Pte Ltd.

Further, we also enclose a declaration on unmodified opinion in the Auditors' Report for the financial year ended March 31, 2025.

Also, BSE Limited to hereby take note of the following in respect of the debt securities of the Company, **Scrip Code: 975645**; that the Company has fully redeemed its 20,000, listed, secured, rated, redeemable Non-Convertible Debentures, on November 28, 2024, therefore the following intimations are not required:

- i) Intimation of security cover certificate for the quarter ended March 31, 2025 under Regulation 54 and 56 (1) (d) of SEBI Listing Regulations, along with the financial results.
- ii) Intimation of Statement of utilisation of issue proceeds under Regulation 52 (7) and intimation of material deviations, if any of the issue proceeds under 52 (7A) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') for the quarter ended March 31, 2025.



Corporate Office:
Star 1, Opp IIM Bangalore, Bilekahalli,
Bannerghatta Road, Bengaluru –
560076, India
T: +91 80 6784 0738

Registered Office:
Cyber One, Unit No. 902, Sector 30A
Plot No - 4 & 6, Vashi, Navi Mumbai
400703 India
F: +91 22 2789 2924
T: 91 22 2789 2942

The above information is also available on the website of the Company i.e. <https://www.onesourcecdmo.com/investor-relations/stock-exchange-intimation/>. You are requested to kindly take the same on record.

For and on behalf of
OneSource Specialty Pharma Limited

Trisha A Digitally signed by
Trisha A
Date: 2025.05.05
19:20:53 +5'30

Trisha A
Company Secretary and Compliance Officer
Membership Number: A47635



INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL STANDALONE FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF ONESOURCE SPECIALITY PHARMA LIMITED (FORMERLY KNOWN AS STELIS BIOPHARMA LIMITED)

Opinion and Conclusion

We have (a) audited the Standalone Financial Results for the year ended March 31, 2025 and (b) reviewed the Standalone Financial Results for the quarter ended March 31, 2025 (refer 'Other Matters' section below), which were subject to limited review by us, both included in the accompanying Statement of Standalone Financial Results for the quarter and year ended March 31, 2025 of **Onesource Speciality Pharma Limited (formerly known as Stelis Biopharma Limited)** (the "Company"), (the "Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "LODR Regulations").

(a) Opinion on Annual Standalone Financial Results

In our opinion and to the best of our information and according to the explanations given to us, the Standalone Financial Results for the year ended March 31, 2025:

- i. are presented in accordance with the requirements of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- ii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information of the Company for the year then ended.

(b) Conclusion on Unaudited Standalone Financial Results for the quarter ended March 31, 2025

With respect to the Standalone Financial Results for the quarter ended March 31, 2025, based on our review conducted as stated in paragraph (b) of Auditor's Responsibilities section below, nothing has come to our attention that causes us to believe that the Standalone Financial Results for the quarter ended March 31, 2025, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Basis for Opinion on the Audited Standalone Financial Results for the year ended March 31, 2025

We conducted our audit in accordance with the Standards on Auditing ("SA's") specified under Section 143(10) of the Companies Act, 2013 (the "Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section

Deloitte Haskins & Sells

below. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (the "ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Results for the year ended March 31, 2025 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

Management's and Board of Directors' Responsibilities for the Statement

This Statement which includes the Standalone Financial Results is the responsibility of the Company's Board of Directors and has been approved by them for the issuance. The Standalone Financial Results for the year ended March 31, 2025 has been compiled from the related audited standalone financial statements. This responsibility includes the preparation and presentation of the Standalone Financial Results for the quarter and year ended March 31, 2025 that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52 of the LODR Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Results, the Board of Directors is responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities

(a) Audit of the Standalone Financial Results for the year ended March 31, 2025

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results for the year ended March 31, 2025 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Standalone Financial Results.

Deloitte Haskins & Sells

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 and Regulation 52 of the LODR Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual Standalone Financial Results, including the disclosures, and whether the Annual Standalone Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the Annual Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Standalone Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to

Deloitte Haskins & Sells

communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

(b) Review of the Standalone Financial Results for the quarter ended March 31, 2025

We conducted our review of the Standalone Financial Results for the quarter ended March 31, 2025 in accordance with the Standard on Review Engagements ("SRE") 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under Section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Other Matters

- As stated in Note 3 of the Statement, financial information relating to the corresponding quarter ended March 31, 2024 as reported in the accompanying Statement have been approved by the Company's Board of Directors, but have not been subjected to review or audit by us. The financial information for the year ended March 31, 2024 have been replicated in the Statement from the financial statements which was audited by us based on requirements of Companies Act, 2013. Our report is not modified in respect of this matter.
- The Statement includes the results for the quarter ended March 31, 2025 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us. Our report on the Statement is not modified in respect of this matter.

For **Deloitte Haskins & Sells**
Chartered Accountants
(Firm's Registration No.008072S)

Sandeep
Ramesh
Kukreja

Digitally signed by
Sandeep Ramesh
Kukreja
Date: 2025.05.05
17:19:19 +05'30'

Sandeep Kukreja
Partner

(Membership No. 220411)
(UDIN: 25220411BMOQCQ2747)

Place: Bengaluru
Date: May 5, 2025

CIN: L74140MH2007PLC432497, Website : <https://www.onesourcecdmo.com>, Mail: info@onesourcecdmo.com

Rs. in Million, except per share data

[illegible]

OneSource Specialty Pharma Limited (formerly known as Stelis Biopharma Limited)
Registered Office : Unit no. 902, " Cyber One" situated at Plot no.-4 & 6, Sector 30A, Vashi, Navi Mumbai - 400703
Corporate Office : Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road, Bangalore - 560076, India
CIN: L74140MH2007PLC432497, **Website :** <https://www.onesourcecdmo.com>, **Mail:** info@onesourcecdmo.com

Statement of Standalone Financial Results for the quarter and year ended March 31, 2025

Standalone Balance Sheet as at March 31, 2025

Rs. in Million		
Particulars	As at March 31, 2025	As at March 31, 2024
	Audited	(Refer note 3)
ASSETS		
I Non-current assets		
(a) Property, plant and equipment	7,241.58	6,596.46
(b) Right of use assets	1,731.95	227.84
(c) Capital work in progress	603.72	427.35
(d) Goodwill	19,761.42	-
(e) Other intangible assets	3,267.96	1,801.56
(f) Intangible assets under development	1,455.21	1,452.90
(g) Financial assets		
(i) Investments	28,391.73	39.09
(ii) Security deposits	178.97	41.11
(iii) Trade receivables	562.39	-
(h) Other non-current assets	470.89	735.26
Total non-current assets	63,665.82	11,321.57
II Current assets		
1 (a) Inventories	1,534.35	112.31
(b) Financial assets		
(i) Investments	88.83	157.92
(ii) Trade receivables	4,419.72	554.05
(iii) Cash and cash equivalents	832.03	63.98
(iv) Bank balances other than (iii) above	1,444.19	538.56
(v) Security deposits	1.18	-
(vi) Other financial assets	271.71	50.00
(c) Other current assets	1,646.79	287.37
Total current assets	10,238.80	1,764.19
Total assets (I+II)	73,904.62	13,085.76
B. EQUITY AND LIABILITIES		
I Equity		
(a) Equity share capital	114.43	40.10
(b) Other equity	59,086.58	3,937.33
Total Equity	59,201.01	3,977.43
II Liabilities		
1 Non-current liabilities		
(a) Financial Liabilities		
(i) Borrowings	2,193.31	2,715.92
(ii) Lease liabilities	1,631.94	83.22
(iii) Other financial liabilities	13.76	-
(b) Provisions	157.92	23.96
(d) Other non-current liabilities	11.86	-
Total Non-current liabilities	4,008.79	2,823.10
2 Current liabilities		
(a) Financial Liabilities		
(i) Borrowings	5,522.56	2,900.38
(ii) Lease liabilities	76.56	6.87
(iii) Trade payables		
(A) total outstanding dues of micro and small enterprises	113.60	144.46
(B) total outstanding dues of creditors other than micro and small enterprises	1,487.03	664.93
(iv) Other financial liabilities	911.02	1,553.89
(b) Provisions	121.95	42.98
(c) Other current liabilities	2,462.10	971.72
Total Current liabilities	10,694.82	6,285.23
Total Equity and liabilities (I+II)	73,904.62	13,085.76

OneSource Specialty Pharma Limited (formerly known as Stelis Biopharma Limited)
Registered Office : Unit no. 902, " Cyber One" situated at Plot no.-4 & 6, Sector 30A, Vashi, Navi Mumbai - 400703
Corporate Office : Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road, Bangalore - 560076, India
CIN: L74140MH2007PLC432497, **Website :** <https://www.onesourcecdmo.com>, **Mail:** info@onesourcecdmo.com

Statement of Standalone Financial Results for the quarter and year ended March 31, 2025

Standalone Statement of Cash Flows for the year ended March 31, 2025

Particulars	Rs. in Million			
	For the year ended			
	March 31, 2025	March 31, 2024	March 31, 2025	March 31, 2024
	(Audited)	(Refer note 3)		
A. Cash flow from operating activities				
Profit/(Loss) before tax for the year				
Continuing Operations		(214.55)		(3,649.34)
Discontinued Operations		(6.90)		(254.68)
Profit/(Loss) before tax (including discontinued operations)		(221.45)		(3,904.02)
<u>Adjustments for:</u>				
Depreciation and amortisation expenses	1,345.12	953.80		
Finance costs	1,616.50	1,171.63		
Interest income	(160.18)	(32.65)		
Share based payment expenses	43.14	19.56		
Advance written off	-	0.73		
Gain on termination of lease	(1.06)	(38.66)		
Loss on sale of asset	2.25	62.12		
Gain on disposal of assets / settlement of liabilities attributable to the discontinued operations (net)	-	(601.62)		
Provision for bad and doubtful debts attributable of discontinued operations	6.90	-		
Unrealised exchange (gain)/loss (net)	(20.12)	24.99		
<u>Exceptional Items :</u>				
Provision for inventories including Goods and Service tax inputs credits thereon (including the inventories of discontinued operations)	-	1,320.94		
Provision for impairment towards investment in Biolexis Private Limited	4.50	381.82		
Reversal for provision for impairment				
Provision/(reversal of provision) for bad and doubtful debts in Biolexis PTE. Limited.	(95.20)	(45.23)		
Provision/(reversal of provision) for bad and doubtful debts in Biolexis Private Limited	(4.50)	45.15		
Provision / (reversal of provision) towards investment in Biolexis Pte Limited	-	(381.82)		
Provision / (reversal of provision) towards investment in Stelis PTE. Limited	109.25	-		
		2,846.60		2,880.76
Operating profit / (loss) before working capital changes		2,625.15		(1,023.26)
<u>Changes in working capital:</u>				
<u>Adjustments for (increase) / decrease in operating assets:</u>				
Trade receivables	(2,519.06)	(516.68)		
Other assets (financial & non-financial)	(677.34)	(277.21)		
Decrease / (increase) in inventories	165.09	(4.03)		
<u>Adjustments for increase / (decrease) in operating liabilities:</u>				
Trade payables	(509.11)	(163.63)		
Other liabilities (financial & non-financial)	511.42	894.92		
		(3,029.00)		(66.63)
Net cash used for operating activities		(403.85)		(1,089.89)
Income taxes (paid)/refund		(68.98)		-
Net cash used in operating activities (A)		(472.83)		(1,089.89)
B. Cash flow from investing activities				
Capital expenditure on property, plant and equipment including capital advances	(863.13)	(637.67)		
Proceeds from sale of asset	0.93	3.97		
Investments in subsidiaries and others	(1,409.99)	(465.97)		
Proceeds from sale of investment	-	381.83		
Proceeds from sale of multimodal facility	43.10	5,531.70		
Proceeds from termination / (contribution to) of margin money deposits	(890.87)	610.17		
Investment in fixed deposit	(14.76)	(394.23)		
Interest received	134.35	30.09		
Net cash flow from / (used in) investing activities (B)		(3,000.37)		5,059.89
C. Cash flow from financing activities				
Proceeds from calls on partly paid-up shares	802.84	-		
Proceeds from issue of fresh equity shares (net of share issue expenses)	7,952.39	-		
Proceeds from issue of non-convertible debentures	2,000.00	3,958.00		
Redemption of non-convertible debentures	(4,400.50)	(1,057.50)		
Proceeds of related party loan	-	2,539.59		
Repayment of related party loan	(625.83)	(2,904.59)		
Proceeds/(repayment) of short term borrowings (net)	950.53	(1,003.96)		
Proceeds of long-term borrowings	500.00	-		
Repayment of long-term borrowings	(1,279.23)	(4,282.28)		
Lease Payments	(209.85)	(65.63)		
Interest paid	(1,518.19)	(1,025.83)		
Net cash (used in) / flow from financing activities (C)		4,172.16		(3,842.20)

OneSource Specialty Pharma Limited (formerly known as Stelis Biopharma Limited)
Registered Office : Unit no. 902, " Cyber One" situated at Plot no.-4 & 6, Sector 30A, Vashi, Navi Mumbai - 400703
Corporate Office : Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road, Bangalore - 560076, India
CIN: L74140MH2007PLC432497, Website : <https://www.onesourcecdmo.com>, Mail: info@onesourcecdmo.com

Statement of Standalone Financial Results for the quarter and year ended March 31, 2025

Standalone Statement of Cash Flows for the year ended March 31, 2025

Particulars	Rs. in Million			
	For the year ended			
	March 31, 2025		March 31, 2024	
Net increase / (decrease) in cash and cash equivalents (A+B+C)	698.96		127.80	
Cash and cash equivalents at the beginning of the year	221.90		94.10	
Cash and cash equivalents at the end of the year	920.86		221.90	
Reconciliation of cash and cash equivalents with the Standalone Balance Sheet:				
Cash and cash equivalents as per Balance Sheet	832.03		63.98	
Liquid Mutual Funds	88.83		157.92	
Cash and cash equivalents at the end of the year *	920.86		221.90	
* Cash and cash equivalents comprises:				
Cash on hand	0.66		0.03	
Balances with banks				
▪ in current accounts	831.37		63.95	
Liquid Mutual Funds	88.83		157.92	
Total	920.86		221.90	

OneSource Specialty Pharma Limited (formerly known as Stelis Biopharma Limited)
Registered Office : Unit no. 902, " Cyber One" situated at Plot no.-4 & 6, Sector 30A, Vashi, Navi Mumbai - 400703
Corporate Office : Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road, Bangalore - 560076, India
CIN: L74140MH2007PLC432497, **Website :** <https://www.onesourcecdmo.com>, **Mail:** info@onesourcecdmo.com

Notes to the Statement of Standalone Financial Results for the quarter and year ended March 31, 2025

1 In terms of Regulation 33 (refer note 5) and Regulation 52 of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015, ("Listing Requirements"), as amended, the Statement of Standalone Financial Results for the quarter and year ended March 31, 2025 ("Statement") of OneSource Specialty Pharma Limited (formerly known as Stelis Biopharma Limited) ('the Company') has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on May 5, 2025. The results for the year ended March 31, 2025 has been audited and the quarter ended March 31, 2025 has been reviewed by Deloitte Haskins & Sells, the statutory auditors of the Company, who have expressed an unmodified opinion on the financial results for the year ended March 31, 2025 and have issued an unmodified conclusion in respect of the limited review for the quarter ended March 31, 2025.

2 The above Statement has been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) 2015, as amended.

3 The Standalone Financial Information for the quarter ended March 31, 2024 included in the financial results have not been subject to an audit or review by our statutory auditors. However, the Management has exercised necessary due diligence to ensure that the financial information for the said period provide a true and fair view of the Company's affairs. The Standalone Financial Information for the year ended March 31, 2024 has been replicated from the financial statements which was subject to audit by the statutory auditors based on the requirements of the Companies Act, 2013. Also, the Standalone Financial information for the quarter ended December 31, 2024 included in the financial results were only reviewed and not subjected to audit.

4 During the quarter and year ended March 31, 2025 the Company has incurred profit of Rs. 1,748.77 million and Rs. 200.00 million (comparative period loss of Rs. 400.12 million and Rs. 3,649.34 million) respectively. The Company's current liabilities exceeded its current assets by Rs. 456.02 million as at March 31, 2025.

During the year ended March 31, 2025, the Company received Rs. 802.84 million towards pending partly paid-up shares. Also, the Company has issued 6,277,909 equity shares valued at Rs. 1,276 per share aggregates to Rs. 8,010.61 million. The cost of issue of shares of Rs. 58.22 million in relation to equity issue is debited to equity.

The Company expects to grow the business of Contract Development and Manufacturing Operations (CDMO). The Company has also signed several Manufacturing Services Agreements (MSA) for its CDMO business which is expected to convert into Commercial supplies under a Commercial Sales Agreement (CSA) on approval for the customer in future to meet all future obligations as they fall due. Further, the Management is confident that the Scheme of arrangement referred in note below (refer note 5) will enhance business potential and result in an increased capability to offer a wider portfolio of products with a diversified resource base and deeper client relationships.

Based on above, the Board of Directors have approved preparation of the Standalone Financial Results on a going concern basis.

5 Pursuant to the Scheme of Arrangement between parties, the identified CDMO business and Soft Gelatin business of Strides Pharma Science Limited ('Strides') and identified CDMO business of Steriscience Specialities Private Limited ('Steriscience') are merged with the Company.

The Mumbai Bench of the National Company Law Tribunal ("NCLT") has approved the Scheme through its order dated November 14, 2024 (the "Order") with the appointed date of April 01, 2024. The Certified True Copy of the Order along with sanctioned Scheme was received on November 26, 2024. The Scheme became effective on November 27, 2024, upon filing of the certified copies of the NCLT Order sanctioning the Scheme, by all the Companies, with the Registrar of Companies, Maharashtra ("ROC") and accordingly, the effect of the Scheme is given in the current period. Since the Scheme is effective April 01, 2024, the Financial Information for the periods ended March 31, 2025 and December 31, 2024 include the operations of the acquired business and accordingly the previous period figures are not comparable.

This transaction has been accounted for as per the acquisition method specified in Ind AS 103 and accordingly, the difference of Rs. 19,761.42 million between purchase consideration of Rs. 53,963.29 million and fair value of net assets of Rs. 34,201.87 million has been recognised as goodwill. Acquisition related costs are expensed as incurred. The goodwill is attributable to the workforce and capability of business to economies of scale expected from combining the operations resulting in increase in profitability of acquired businesses. It will not be deductible for tax purposes.

Pursuant to the approval of the Scheme of Arrangement by the Hon'ble NCLT, filing of information memorandum with SEBI and the consequent approval, the equity shares of the Company has been listed on BSE Limited (BSE) and National Stock Exchange of India Limited (NSE) (together 'the Stock Exchanges') on January 24, 2025.

As a result of the Scheme, the former shareholders of Strides were issued 1 fully paid equity share for every 2 fully paid equity shares held in Strides and the former shareholders of Steriscience were issued 1,515 fully paid equity shares for every 1 fully paid equity share held in Steriscience on December 10, 2024.

6 During the previous year, the Company entered into a Business Transfer Agreement (BTA) dated September 01, 2023 with Syngene International Limited for sale of Unit-3 (multimodal facility) on a slump sale basis for a consideration of Rs. 7,020 million subject to certain defined conditions precedents. The transaction recommended by Board of Directors is approved by shareholders.

The Company had entered into the Amendment to Business Transfer Agreement dated December 01, 2023 and December 21, 2023 with Syngene for the revised understanding on the assets and liabilities to be transferred by the Company to Syngene and the revised purchase consideration for the transaction is agreed at Rs. 6,170 million. During the quarter ended December 31, 2023, parties as per the BTA have completed the transaction related to divestment of Unit-3.

The Company has classified the Unit-3 multimodal facility related operations which is transferred by the Company to Syngene as discontinued operations in line with the requirements of Ind AS 105 - Non-current assets held for sale and discontinued operations. Refer below for the results of discontinued operations.

Particulars	Quarter ended			Year ended	
	March 31, 2025		March 31, 2024		March 31, 2024
	March 31, 2025	December 31, 2024	March 31, 2024	March 31, 2025	
(I) Total Revenue	-	-	-	-	52.02
(II) Total expenses	6.90	-	-	-	746.80
(III) Loss from discontinued operations (I - II)	(6.90)	-	-	-	(694.78)
(IV) Exceptional items gain / (loss) (net)	-	-	-	-	(161.52)
(V) Loss before tax (III + IV)	(6.90)	-	-	-	(856.30)
(VI) Gain / (loss) on disposal of: Unit 3 Multimodal Facility	-	-	-	-	601.62
(VII) Profit/ (loss) from discontinued operations (V + VI)	(6.90)	-	-	-	(254.68)

OneSource Specialty Pharma Limited (formerly known as Stelis Biopharma Limited)
Registered Office : Unit no. 902, " Cyber One" situated at Plot no.-4 & 6, Sector 30A, Vashi, Navi Mumbai - 400703
Corporate Office : Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road, Bangalore - 560076, India
CIN: L74140MH2007PLC432497, Website : <https://www.onesourcecdmo.com>, Mail: info@onesourcecdmo.com

Notes to the Statement of Standalone Financial Results for the quarter and year ended March 31, 2025

7 Exceptional items (net)

Particulars	Quarter ended			Year ended	
	March 31, 2025	December 31, 2024	March 31, 2024	March 31, 2025	March 31, 2024
Provision related to Inventories (including Goods and Service tax inputs credits thereon)	-	-	0.21	-	1,159.42
Provision/(reversal) towards investment/trade receivables in subsidiaries/step-down subsidiary (net)	-	-	-	14.05	(0.08)
Business combination, listing and post-merger integration related expenses*	-	1,005.23	-	1,108.45	-
Total	-	1,005.23	0.21	1,122.50	1,159.34

* Pertains to expenses incurred towards the Scheme of arrangement and consequent listing of the Company, as referred in note 5 above. Expenses majorly includes legal and professional fees, provisional stamp duty expenses, one-time incentive and awards to employees and interest on prepayment of debt pursuant to the Scheme of arrangement.

- 8 During the year ended March 31, 2025, the Company fully repaid its listed non-convertible debentures. The security against these debentures secured by a pari passu charge over certain specified movable assets, as well as an exclusive charge on specific fixed deposits with the bank are released during the quarter ended March 31, 2025.
- 9 The Company publishes these Standalone Financial Results along with Consolidated Financial Results. In accordance with Ind AS 108, 'Operating Segments', the Company has disclosed the segment information in the Consolidated Financial Results.
- 10 The figures for the quarter ended March 31, 2025 are the balancing figures between audited figures in respect to full financial year and the published unaudited year to date figures upto the end of the third quarter of the relevant financial year, which are subjected to limited review.
- 11 Disclosure as per Regulation 52(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended, are provided as annexure to this Statement.

For and on behalf of Board of Directors of OneSource Specialty Pharma Limited (formerly known as Stelis Biopharma Limited)

NEERAJ SHARMA
Digitally signed by
NEERAJ SHARMA
Date: 2025.05.05
19:17:38 +05'30
Neeraj Sharma
Managing Director
DIN : 09402652

Place : Bengaluru
Date : May 5, 2025

OneSource Specialty Pharma Limited (formerly known as Stelis Biopharma Limited)
Registered Office : Unit no. 902, " Cyber One" situated at Plot no.-4 & 6, Sector 30A, Vashi, Navi Mumbai - 400703
Corporate Office : Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road, Bangalore - 560076, India
CIN: L74140MH2007PLC432497, Website : <https://www.onesourcecdmo.com>, Mail: info@onesourcecdmo.com

Additional disclosures of Standalone Financial Results as per Regulations 52(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Sl. No.	Particulars	Quarter ended			Year ended	
		March 31, 2025	December 31, 2024	March 31, 2024	March 31, 2025	March 31, 2024
1	Debt-Equity Ratio - <i>in times</i> (A) / (B) Debt including lease liabilities(A) Equity (B)	0.16	0.19	1.43	0.16	1.43
2	Debt Service Coverage Ratio - <i>in times</i> (C) / ((D) + (E)) Earnings Before Interest, Taxes, Depreciation and Amortisation (C) Debt repayment (D) Interest payments (E)	2.85	0.27	(0.00)	0.50	(0.11)
3	Interest Service Coverage Ratio (F) / (G) Earnings Before Interest and Taxes (F) Interest payments (G)	7.38	1.86	(1.11)	1.78	(1.97)
4	Outstanding redeemable preference shares (quantity and value)	NA	NA	NA	NA	NA
5	Capital redemption reserve/debenture redemption reserve	NA	NA	NA	NA	NA
6	Net worth (million) (as per Section 2(57) of Companies Act,2013)	59,201.01	57,480.28	3,977.43	59,201.01	3,977.43
7	Net profit after tax	1,748.77	(730.23)	(400.12)	200.00	(3,649.34)
8	Current Ratio - <i>in times</i> (H) / (I) Current Assets (H) Current Liabilities (I)	0.96	0.88	0.28	0.96	0.28
9	Long term debt to working capital - <i>in times</i> (J) / (K) Non-current borrowings including lease liabilities (J) Working capital (Current assets - Current liabilities) (K)	(8.39)	(2.52)	(0.62)	(8.39)	(0.62)
10	Bad Debts to accounts receivable ratio (L) / (M) Bad Debts (L) Average trade receivables (M)	NA	NA	NA	NA	0.15
11	Current Liability ratio (N)/(O) Total Current liabilities (N) Total Liabilities (O)	0.73	0.76	0.69	0.73	0.69
12	Total debt to total assets ratio (P) / (Q) Total Borrowings including lease liabilities (P) Total Assets (Q)	0.13	0.15	0.44	0.13	0.44
13	Trade receivables turnover ratio (R) / (S) Revenue from operations (R) Average Trade receivables (S)	0.94	0.71	1.96	4.69	5.81
14	Inventory turnover ratio (T) / (U) Consumables (T) Average Inventory (U)	0.73	0.66	1.81	4.96	0.98
15	Operating margin % (V) / (W) Earnings Before Interest, Taxes, Depreciation & Amortisation and exceptional items (-) Other income (V) Revenue from operations (W)	49.63%	29.54%	-3.65%	28.41%	-50.91%
16	Net profit margin % (X) / (Y) Net profit (X) Gross Revenue (Y)	36.33%	-21.31%	-52.80%	1.52%	-207.18%

Note: The figures for the reported periods have been provided for comparison purposes.

INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL CONSOLIDATED FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF ONESOURCE SPECIALTY PHARMA LIMITED (FORMERLY KNOWN AS STELIS BIOPHARMA LIMITED)

Opinion and Conclusion

We have (a) audited the Consolidated Financial Results for the year ended March 31, 2025 and (b) reviewed the Consolidated Financial Results for the quarter ended March 31, 2025 (refer 'Other Matters' section below), which were subject to limited review by us, both included in the accompanying Statement of Consolidated Financial Results for the quarter and year ended March 31, 2025 of **Onesource Specialty Pharma Limited (formerly known as Stelis Biopharma Limited)** (the "Parent Company") and its subsidiaries (the Parent Company and its subsidiaries together referred to as the "Group"), (the "Statement"), being submitted by the Parent Company pursuant to the requirements of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "LODR Regulations").

(a) Opinion on Annual Consolidated Financial Results

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the audit reports of other auditors on separate financial statements of subsidiaries referred to in Other Matters section below, the Consolidated Financial Results for the year ended March 31, 2025:

- (i) includes the financial results of the following entities:
 - Parent Company
OneSource Specialty Pharma Limited
 - Subsidiary Companies (including step-down subsidiary companies)
 - a. Biolexis Private Limited
 - b. Biolexis PTE. Ltd
 - c. Stelis PTE Limited
 - d. OneSource Specialty PTE. Limited (formerly known as Steriscience Specialities PTE. Limited)
 - e. Strides Softgels PTE. Ltd.
 - f. Strides Pharma Services Private Limited
- (ii) are presented in accordance with the requirements of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- (iii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the consolidated net loss and consolidated other comprehensive loss and other financial information of the Group for the year ended March 31, 2025.

Deloitte Haskins & Sells

(b) Conclusion on Unaudited Consolidated Financial Results for the quarter ended March 31, 2025

With respect to the Consolidated Financial Results for the quarter ended March 31, 2025, based on our review conducted and procedures performed as stated in paragraph (b) of Auditor's Responsibilities section below and based on the consideration of the review reports of the other auditors referred to in Other Matters section below, nothing has come to our attention that causes us to believe that the Consolidated Financial Results for the quarter ended March 31, 2025, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Basis for Opinion on the Audited Consolidated Financial Results for the year ended March 31, 2025

We conducted our audit in accordance with the Standards on Auditing ("SA"s) specified under Section 143(10) of the Companies Act, 2013 (the "Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (the "ICAI") together with the ethical requirements that are relevant to our audit of the Consolidated Financial Results for the year ended March 31, 2025 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us and the audit evidence obtained by the other auditors in terms of their reports referred to in Other Matters section below, is sufficient and appropriate to provide a basis for our audit opinion.

Management's and Board of Directors' Responsibilities for the Statement

This Statement, which includes the Consolidated Financial Results is the responsibility of the Parent Company's Board of Directors and has been approved by them for the issuance. The Consolidated Financial Results for the year ended March 31, 2025, has been compiled from the related audited consolidated financial statements. This responsibility includes the preparation and presentation of the Consolidated Financial Results for the quarter and year ended March 31, 2025 that give a true and fair view of the consolidated net loss and consolidated other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards, prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52 of the LODR Regulations.

The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the respective financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been

Deloitte Haskins & Sells

used for the purpose of preparation of this Consolidated Financial Results by the Directors of the Parent Company, as aforesaid.

In preparing the Consolidated Financial Results, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the respective entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate their respective entities or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities

(a) Audit of the Consolidated Financial Results for the year ended March 31, 2025

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Results for the year ended March 31, 2025 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Consolidated Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Consolidated Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 and Regulation 52 of the LODR Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report

Deloitte Haskins & Sells

to the related disclosures in the Consolidated Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the Annual Consolidated Financial Results, including the disclosures, and whether the Annual Consolidated Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Perform procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the LODR Regulations to the extent applicable.
- Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Results entities within the Group to express an opinion on the Annual Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Annual Consolidated Financial Results of which we are the independent auditors. For the entities included in the Annual Consolidated Financial Results, which have been audited by the other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatements in the Annual Consolidated Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Consolidated Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Consolidated Financial Results.

We communicate with those charged with governance of the Parent Company and such other entities included in the Consolidated Financial Results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

(b) Review of the Consolidated Financial Results for the quarter ended March 31, 2025

We conducted our review of the Consolidated Financial Results for the quarter ended March 31, 2025 in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under Section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Deloitte Haskins & Sells

The Statement includes the results of the entities as listed under paragraph (a)(i) of Opinion and Conclusion section above.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

Other Matters

- As stated in Note 3 of the Statement, financial information relating to the corresponding quarter ended March 31, 2024, as reported in the accompanying Statement have been approved by the Parent Company's Board of Directors, but have not been subjected to audit or review by us. The financial information for the year ended March 31, 2024 have been replicated in the Statement from the financial statements which was audited by us based on requirements of the Companies Act, 2013. Our report is not modified in respect of this matter.
- The Statement includes the results for the quarter ended March 31, 2025 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us. Our report is not modified in respect of this matter.
- We did not audit the financial statements/ financial information of 6 subsidiaries (including step-down subsidiaries) included in the consolidated financial results, whose financial statements reflect total assets of Rs. 4,851.87 million as at March 31, 2025 and total revenues of Rs. 1,636.78 million and Rs. 7,902.46 million for the quarter and year ended March 31, 2025 respectively, total net profit / (loss) after tax of Rs. (404.13) million and Rs. 622.87 million for the quarter and year ended March 31, 2025 respectively and other comprehensive income / (loss) of Rs. (403.24) million and Rs. 622.87 million for the quarter and year ended March 31, 2025 respectively and net cash inflows of Rs. 14.06 million for the year ended March 31, 2025, as considered in the Statement. These financial statements/ financial information have been audited/ reviewed, as applicable, by other auditors whose reports have been furnished to us by the Management and our opinion and conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated under Auditor's Responsibilities section above.

Our report on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors.

For **Deloitte Haskins & Sells**
Chartered Accountants
(Firm's Registration No.008072S)

Sandeep
Ramesh
Kukreja

Digitally signed by
Sandeep Ramesh
Kukreja
Date: 2025.05.05
17:21:20 +05'30'

Sandeep Kukreja
Partner
(Membership No. 220411)
(UDIN: 25220411BMOQCR2292)

Place: Bengaluru
Date: May 5, 2025

OneSource Specialty Pharma Limited (formerly known as Stelis Biopharma Limited)

Registered Office : Unit no. 902, "Cyber One" situated at Plot no.-4 & 6, Sector 30A, Vashi, Navi Mumbai-400703

Corporate Office : Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road, Bangalore - 560076, India

CIN: L74140MH2007PLC432497, Website : <https://www.onesourcecdmo.com>, Mail: info@onesourcecdmo.com

Statement of Consolidated Financial Results for the quarter and year ended March 31, 2025

Rs. in Million, except per share data

Sl No	Particulars	Quarter ended			Year ended	
		March 31, 2025	December 31, 2024	March 31, 2024	March 31, 2025	March 31, 2024
		(Refer note 12)	(Unaudited)	(Refer note 3)	(Audited)	(Refer note 3)
A.	Continuing Operations					
	Income					
1	Revenue from operations	4,259.53	3,925.63	731.43	14,448.53	1,719.19
2	Other income	28.90	67.18	26.36	174.74	42.25
3	Total income (1+2)	4,288.43	3,992.81	757.79	14,623.27	1,761.44
4	Expenses					
	(a) Cost of materials consumed	909.93	816.21	-	3,282.41	-
	(b) Changes in inventories of finished goods and work-in-progress	(79.54)	86.74	-	301.02	-
	(c) Consumables	278.67	112.40	187.38	766.91	705.09
	(d) Employee benefits expenses	510.61	573.49	203.63	2,152.59	793.61
	(e) Finance costs	334.12	458.21	204.56	1,663.24	894.48
	(f) Depreciation and amortisation expenses	684.91	687.65	195.29	2,738.84	762.93
	(g) Other expenses	814.71	917.90	368.42	3,280.47	1,102.88
	Total expenses (4)	3,453.41	3,652.60	1,159.28	14,185.48	4,258.99
5	Profit/(loss) before exceptional items and tax (3-4)	835.02	340.21	(401.49)	437.79	(2,497.55)
6	Exceptional items (refer note 8)	-	(1,005.23)	(0.21)	(1,108.45)	(1,159.42)
7	Profit/(Loss) before tax (5+6)	835.02	(665.02)	(401.70)	(670.66)	(3,656.97)
8	Income tax expense					
	Current tax	(106.94)	59.68	-	118.33	-
	Deferred tax	(49.96)	(36.21)	-	(616.18)	-
	Total tax expense	(156.90)	23.47	-	(497.85)	-
9	Profit/(Loss) after tax (7-8)	991.92	(688.49)	(401.70)	(172.81)	(3,656.97)
B.	Discontinued Operations (refer note 6)					
	(i) Loss from discontinued operations	(6.90)	-	-	(6.90)	(856.30)
	(ii) Gain on disposal of assets / settlement of liabilities attributable to the discontinued operations (net)	-	-	-	-	601.62
	(iii) Tax expense of discontinued operations	-	-	-	-	-
10	Profit/(Loss) after tax from discontinued operations	(6.90)	-	-	(6.90)	(254.68)
11	Profit/(Loss) for the year (9+10)	985.02	(688.49)	(401.70)	(179.71)	(3,911.65)
12	Other Comprehensive Income					
	Items that will not be reclassified to statement of profit and loss					
	- Remeasurements of post employment benefit obligations- (loss) / gain	0.79	-	0.04	(29.65)	(5.25)
	- Income tax relating to these items	-	-	-	-	-
	Items that may be reclassified to statement of profit and loss					
	- Exchange differences in translating the financial statements of foreign operations	21.10	(18.70)	1.12	(2.10)	(0.06)
	Total other comprehensive income/ (loss)	21.89	(18.70)	1.16	(31.75)	(5.31)
13	Total comprehensive income/(loss) for the year (11+12)	1,006.91	(707.19)	(400.54)	(211.46)	(3,916.96)
14	Paid-up equity share capital (of Rs. 1/- each)	114.43	114.43	40.10	114.43	40.10
	Reserves (Other Equity)				58,691.36	3,917.03
15	Earnings/ (Loss) per share (of Rs. 1/- each) (for continuing operations):	(not annualised)	(not annualised)	(not annualised)	(annualised)	(annualised)
	- Basic	8.67	(6.31)	(9.67)	(1.57)	(88.02)
	- Diluted	8.65	(6.31)	(9.67)	(1.57)	(88.02)
	Earnings/ (Loss) per share (of Rs. 1/- each) (for discontinued operations):					
	- Basic	(0.06)	-	-	(0.06)	(6.13)
	- Diluted	(0.06)	-	-	(0.06)	(6.13)
	Earnings/ (Loss) per share (of Rs. 1/- each) (for total operations):					
	- Basic	8.61	(6.31)	(9.67)	(1.63)	(94.15)
	- Diluted	8.59	(6.31)	(9.67)	(1.63)	(94.15)

See accompanying notes to Consolidated Financial Results for the quarter and year ended March 31, 2025

OneSource Specialty Pharma Limited (formerly known as Stelis Biopharma Limited)

Registered Office : Unit no. 902, " Cyber One" situated at Plot no.-4 & 6, Sector 30A, Vashi, Navi Mumbai-400703

Corporate Office : Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road, Bangalore - 560076, India

CIN: L74140MH2007PLC432497, Website : <https://www.onesourcecdmo.com>, Mail: info@onesourcecdmo.com

Statement of Consolidated Financial Results for the quarter and year ended March 31, 2025

Consolidated Balance Sheet as at March 31, 2025

Particulars	Rs. in Million	
	As at March 31, 2025	As at March 31, 2024
	(Audited)	(Refer note 3)
A. ASSETS		
I Non-current assets		
(a) Property, plant and equipment	7,241.58	6,596.46
(b) Right of use assets	1,731.95	227.84
(c) Capital work in progress	603.72	427.35
(d) Goodwill	38,275.31	-
(e) Other intangible assets	13,926.40	1,801.56
(f) Intangible assets under development	1,580.34	1,452.90
(g) Financial assets		
(i) Investments	69.06	37.91
(ii) Security deposits	178.97	41.11
(iii) Trade receivables	562.39	-
(g) Other non-current assets	470.89	737.17
Total non-current assets	64,640.61	11,322.30
II Current assets		
1 (a) Inventories	1,580.62	112.31
(b) Financial assets		
(i) Investments	88.83	157.92
(ii) Trade receivables	4,165.97	552.39
(iii) Cash and cash equivalents	1,564.76	64.72
(iv) Bank balances other than (iii) above	1,444.19	538.56
(v) Security deposits	1.18	-
(vi) Other financial assets	312.15	50.00
(c) Other current assets	1,704.11	287.91
Total current assets	10,861.81	1,763.81
Total assets (I+II)	75,502.42	13,086.11
B. EQUITY AND LIABILITIES		
I Equity		
(a) Equity share capital	114.43	40.10
(b) Other equity	58,691.36	3,917.03
Total Equity	58,805.79	3,957.13
II Liabilities		
1 Non-current liabilities		
(a) Financial Liabilities		
(i) Borrowings	2,193.31	2,715.92
(ii) Lease liabilities	1,631.94	83.22
(iii) Other financial liabilities	13.76	-
(b) Provisions	157.92	23.96
(c) Deferred tax liabilities (net)	1,552.21	-
(d) Other non-current liabilities	11.86	-
Total Non-current liabilities	5,561.00	2,823.10
2 Current liabilities		
(a) Financial Liabilities		
(i) Borrowings	5,522.56	2,905.72
(ii) Lease liabilities	76.56	6.87
(iii) Trade payables		
(A) total outstanding dues of micro and small enterprises	115.31	144.46
(B) total outstanding dues of creditors other than micro and small enterprises	1,639.79	665.77
(iv) Other financial liabilities	1,016.01	1,568.35
(b) Provisions	122.26	42.98
(c) Current tax liabilities	117.24	-
(d) Other current liabilities	2,525.90	971.73
Total Current liabilities	11,135.63	6,305.88
Total Equity and liabilities (I+II)	75,502.42	13,086.11

Onesource Specialty Pharma Limited (formerly known as Stelis Biopharma Limited)
Registered Office : Unit no. 902, " Cyber One" situated at Plot no.-4 & 6, Sector 30A, Vashi, Navi Mumbai-400703
Corporate Office : Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road, Bangalore - 560076, India
CIN: L74140MH2007PLC432497, Website : <https://www.onesourcecdmo.com>, Mail: info@onesourcecdmo.com

Statement of Consolidated Financial Results for the quarter and year ended March 31, 2025

Consolidated Statement of Cash Flows for the year ended March 31, 2025

Particulars	Rs. in Million	
	Year ended	
	March 31, 2025	March 31, 2024
	(Audited)	(Refer note 3)
A. Cash flow from operating activities		
Profit/(Loss) before tax for the year		
Continuing Operations	(670.66)	(3,656.97)
Discontinuing Operations	(6.90)	(254.68)
Profit/(Loss) before tax for the year (including discontinuing operations)	(677.56)	(3,911.65)
<u>Adjustments for:</u>		
Depreciation and amortisation expenses	2,738.84	953.80
Finance costs	1,663.24	1,171.63
Interest income	(158.11)	(32.65)
Share based payment expenses	43.13	19.56
Advance written off	-	0.73
Gain on termination of lease	(1.06)	(38.66)
Loss on sale of asset	2.25	62.12
Gain on disposal of assets / settlement of liabilities attributable to the discontinued operations (net)	-	(601.62)
Provision/(reversal of provision) for bad and doubtful debts attributable of discontinued operations	6.90	-
Unrealised exchange (gain)/loss (net)	(27.19)	24.99
<u>Exceptional Items :-</u>		
Provision for inventories including Goods and Service tax inputs credits thereon (including the inventories of discontinued operations)	-	1,320.94
	4,268.00	2,880.84
Operating loss before working capital changes	3,590.44	(1,030.81)
<u>Changes in working capital:</u>		
<u>Adjustments for (increase) / decrease in operating assets:</u>		
Trade receivables	(2,571.20)	(514.17)
Other assets (financial & non-financial)	(748.67)	(256.71)
Decrease / (increase) in inventories	439.93	(4.03)
<u>Adjustments for increase / (decrease) in operating liabilities:</u>		
Trade payables	(1,176.46)	(160.94)
Other liabilities (financial & non-financial)	(142.46)	894.55
	(4,198.86)	(41.30)
Net cash used for operating activities	(608.42)	(1,072.11)
Income taxes (paid) / refund	(70.12)	-
Net cash used in operating activities (A)	(678.54)	(1,072.11)
B. Cash flow from investing activities		
Capital expenditure on property, plant and equipment including capital advances	(1,281.48)	(637.67)
Proceeds from sale of asset	0.92	3.97
Investments in subsidiaries	-	(37.91)
Proceeds from sale of multimodal facility	43.10	5,531.70
Proceeds from termination / (contribution to) of margin money deposits	(905.63)	610.17
Investment in fixed deposit	-	(394.23)
Interest received	132.28	29.42
Net cash flow from / (used in) investing activities (B)	(2,010.81)	5,105.45

Onesource Specialty Pharma Limited (formerly known as Stelis Biopharma Limited)
Registered Office : Unit no. 902, " Cyber One" situated at Plot no.-4 & 6, Sector 30A, Vashi, Navi Mumbai-400703
Corporate Office : Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road, Bangalore - 560076, India
CIN: L74140MH2007PLC432497, Website : <https://www.onesourcecdmo.com>, Mail: info@onesourcecdmo.com

Statement of Consolidated Financial Results for the quarter and year ended March 31, 2025

Consolidated Statement of Cash Flows for the year ended March 31, 2025

Particulars	Rs. in Million	
	Year ended	
	March 31, 2025	March 31, 2024
C. Cash flow from financing activities		
Proceeds from calls on partly paid-up shares	802.84	-
Proceeds from issue of fresh equity shares	7,952.39	-
Proceeds from issue of non-convertible debentures	2,000.00	3,907.20
Redemption of non-convertible debentures	(4,400.50)	(1,057.50)
Proceeds of related party loan	-	2,545.01
Repayment of related party loan	(630.65)	(2,909.49)
Proceeds/(repayment) of short term borrowings (net)	950.53	(1,303.45)
Proceeds of long-term borrowings	500.00	-
Repayment of long-term borrowings	(1,279.23)	(3,988.79)
Lease Payments	(209.85)	(65.63)
Interest paid	(1,565.45)	(1,032.79)
Net cash (used in) / flow from financing activities (C)	4,120.08	(3,905.44)
Net increase / (decrease) in cash and cash equivalents (A+B+C)	1,430.73	127.90
Cash and cash equivalents at the beginning of the year	222.64	94.74
Adjustment: Addition of cash and cash equivalents on account business combination	0.22	-
Cash and cash equivalents at the end of the year	1,653.59	222.64
Reconciliation of cash and cash equivalents with the Balance Sheet:		
Cash and cash equivalents as per Balance Sheet	1,564.76	64.72
Liquid Mutual Funds	88.83	157.92
Cash and cash equivalents at the end of the year *	1,653.59	222.64
* Cash and cash equivalents comprises:		
Cash on hand	0.65	0.03
Balances with banks		
- in current accounts	1,564.11	64.69
Liquid Mutual Funds	88.83	157.92
Total	1,653.59	222.64

OneSource Specialty Pharma Limited (formerly known as Stelis Biopharma Limited)
Registered Office : Unit no. 902, " Cyber One" situated at Plot no.-4 & 6, Sector 30A, Vashi, Navi Mumbai-400703
Corporate Office : Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road, Bangalore - 560076, India
CIN: L74140MH2007PLC432497, **Website :** <https://www.onesourcecdmo.com>, **Mail:** info@onesourcecdmo.com

Notes to the Statement of Consolidated Financial Results for the quarter and year ended March 31, 2025

- In terms of Regulation 33 (refer note 5) and Regulation 52 of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015, ("Listing Requirements"), as amended, the Statement of Consolidated Financial Results for the quarter and year ended March 31, 2025 ("Statement") of OneSource Specialty Pharma Limited (formerly known as Stelis Biopharma Limited) ('the Parent' or 'the Company') and its subsidiaries (together referred to as 'the Group') has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on May 5, 2025. The results for the year ended March 31, 2025 has been audited and the quarter ended March 31, 2025 has been reviewed by Deloitte Haskins & Sells, the statutory auditors of the Company, who have expressed an unmodified opinion on the financial results for the year ended March 31, 2025 and have issued an unmodified conclusion in respect of the limited review for the quarter ended March 31, 2025.
- The above Statement has been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Listing Requirements, as amended.
- The Consolidated Financial Information for the quarter ended March 31, 2024 included in the financial results have not been subject to an audit or review by our statutory auditors. However, the Management has exercised necessary due diligence to ensure that the Financial Information for the said period provide a true and fair view of the Company's affairs. The Consolidated Financial Information for the year ended March 31, 2024 has been replicated from the Financial Statements which was subject to audit by the statutory auditors based on the requirements of the Companies Act, 2013. Also, the Consolidated Financial information for the quarter ended December 31, 2024 included in the financial results were only reviewed and not subjected to audit.
- During the quarter and year ended March 31, 2025 the Group has incurred profit/ (loss) of Rs. 991.92 million and Rs. (172.81) million (comparative period loss of Rs. 401.70 million and Rs. 3,656.97 million) respectively. The Group's current liabilities exceeded its current assets by Rs. 273.82 million as at March 31, 2025.

During the year ended March 31, 2025, the Group received Rs. 802.84 million towards pending partly paid-up shares. Also, the Group has issued 6,277,909 equity shares valued at Rs. 1276 per share aggregates to Rs. 8,010.61 million. The cost of issue of shares of Rs. 58.22 million in relation to equity issue is debited to equity

The Group expects to grow the business of Contract Development and Manufacturing Operations (CDMO). The Group has also signed several Manufacturing Services Agreements (MSA) for its CDMO business which is expected to convert into Commercial supplies under a Commercial Sales Agreement (CSA) on approval for the customer in future to meet all future obligations as they fall due. Further, the Management is confident that the Scheme of arrangement referred in note below (refer note 5) will enhance business potential and result in an increased capability to offer a wider portfolio of products with a diversified resource base and deeper client relationships.

Based on above, the Board of Directors have approved preparation of Consolidated Financial Results on a going concern basis.

- Pursuant to the Scheme of Arrangement between parties, the identified CDMO business and Soft Gelatin business of Strides Pharma Science Limited ('Strides') and identified CDMO business of Steriscience Specialities Private Limited ('Steriscience') are merged with the Company.

The Mumbai Bench of the National Company Law Tribunal ("NCLT") has approved the Scheme through its order dated November 14, 2024 (the "Order") with the appointed date of April 01, 2024. The Certified True Copy of the Order along with sanctioned the Scheme was received on November 26, 2024. The Scheme became effective on November 27, 2024, upon filing of the certified copies of the NCLT Order sanctioning the Scheme, by all the Companies, with the Registrar of Companies, Maharashtra ("ROC") and accordingly, the effect of the Scheme is given in the current period. Since the Scheme is effective April 01, 2024, the Financial Information for the periods ended March 31, 2025 and December 31, 2024 include the operations of the acquired business and accordingly the previous period figures are not comparable.

This transaction has been accounted for as per the acquisition method specified in Ind AS 103 and accordingly, the difference of Rs. 38,275.31 million between purchase consideration of Rs. 53,963.29 million and fair value of net assets of Rs. 15,687.98 million has been recognised as goodwill. Acquisition related costs are expensed as incurred. The goodwill is attributable to the workforce and capability of business to economies of scale expected from combining the operations resulting in increase in profitability of acquired businesses. It will not be deductible for tax purposes.

Pursuant to the approval of the Scheme of Arrangement by the Hon'ble NCLT and the Scheme becoming effective, the equity shares of the Company has been listed on BSE Limited (BSE) and National Stock Exchange of India Limited (NSE) (together 'the Stock Exchanges') dated January 24, 2025.

As a result of the Scheme, the former shareholders of Strides were issued 1 fully paid equity share for every 2 fully paid equity shares held in Strides and the former shareholders of Steriscience were issued 1,515 fully paid equity shares for every 1 fully paid equity share held in Steriscience dated December 10, 2024.

- During the previous year, the Company entered into a Business Transfer Agreement (BTA) dated September 01, 2023 with Syngene International Limited for sale of Unit-3 (multimodal facility) on a slump sale basis for a consideration of Rs. 7,020 million subject to certain defined conditions precedents. The transaction recommended by Board of Directors is approved by shareholders. .

The Company had entered into the Amendment to Business Transfer Agreement dated December 01, 2023 and December 21, 2023 with Syngene for the revised understanding on the assets and liabilities to be transferred by the Company to Syngene and the revised purchase consideration for the transaction is agreed at Rs. 6,170 million. During the quarter ended December 31, 2023, parties as per the BTA have completed the transaction related to divestment of Unit-3.

The Company has classified the Unit-3 multimodal facility related operations which is transferred by the Company to Syngene as discontinued operations in line with the requirements of Ind AS 105 - Non-current assets held for sale and discontinued operations. Refer below for the results of discontinued operations.

Particulars	Quarter ended			Year ended	
	March 31, 2025	December 31, 2024	March 31, 2024	March 31, 2025	March 31, 2024
(I) Total Revenue	-	-	-	-	52.02
(II) Total expenses	6.90	-	-	6.90	746.80
(III) Loss from discontinued operations (I - II)	(6.90)	-	-	(6.90)	(694.78)
(IV) Exceptional items gain / (loss) (net)	-	-	-	-	(161.52)
(V) Loss before tax (III + IV)	(6.90)	-	-	(6.90)	(856.30)
(VI) Gain / (loss) on disposal of: Unit 3 Multimodal Facility	-	-	-	-	601.62
(VII) Profit/ (loss) from discontinued operations (V + VI)	(6.90)	-	-	(6.90)	(254.68)

OneSource Specialty Pharma Limited (formerly known as Stelis Biopharma Limited)
Registered Office : Unit no. 902, "Cyber One" situated at Plot no.-4 & 6, Sector 30A, Vashi, Navi Mumbai-400703
Corporate Office : Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road, Bangalore - 560076, India
CIN: L74140MH2007PLC432497, Website : <https://www.onesourcecdmo.com>, Mail: info@onesourcecdmo.com

Notes to the Statement of Consolidated Financial Results for the quarter and year ended March 31, 2025

- 7 Based on the Management approach as defined in Ind AS 108, the Chief Operating Decision Maker ("CODM") evaluates the Company's performance based on an analysis of various performance indicators. The accounting principles used in the preparation of these financial results are consistently applied to record revenue and non current assets in individual segments.

The Company's reportable segment are as follows, "CDMO (Contract Development and Manufacturing Organization (CDMO) : Development and manufacture of pharmaceutical products and associated services) and "Unit-3 : Multimodal Facility and CDMO-2" (divested during the year ended March 31, 2024)).

(i) Segment revenue from operations

Particulars	Quarter ended			Year ended	
	March 31, 2025	December 31, 2024	March 31, 2024	March 31, 2025	March 31, 2024
CDMO	4,259.53	3,925.63	731.43	14,448.53	1,719.19
Unit 3 : Multimodal facility and CDMO - 2	-	-	-	-	35.35
Total	4,259.53	3,925.63	731.43	14,448.53	1,754.54

(ii) Segment Profit/ (loss) before tax

Particulars	Quarter ended			Year ended	
	March 31, 2025	December 31, 2024	March 31, 2024	March 31, 2025	March 31, 2024
CDMO	835.02	(665.02)	(401.70)	(670.66)	(3,656.97)
Unit 3 : Multimodal facility and CDMO - 2	(6.90)	-	-	-	(254.68)
Total	828.12	(665.02)	(401.70)	(670.66)	(3,911.65)

(iii) Segment assets*

Particulars	Quarter ended			Year ended	
	March 31, 2025	December 31, 2024	March 31, 2024	March 31, 2025	March 31, 2024
CDMO	63,830.19	65,046.90	11,243.28	63,830.19	11,243.28
Unit 3 : Multimodal facility and CDMO - 2	-	-	-	-	-
Total	63,830.19	65,046.90	11,243.28	63,830.19	11,243.28

*Non-current assets do not include financial assets under financial instruments.

8 Exceptional item:

Particulars	Quarter ended			Year ended	
	March 31, 2025	December 31, 2024	March 31, 2024	March 31, 2025	March 31, 2024
Provision related to Inventories (including Goods and Service tax credits thereon)	-	-	0.21	-	1,159.42
Business combination, listing and post-merger integration related expenses*	-	1,005.23	-	1,108.45	-
Total	-	1,005.23	0.21	1,108.45	1,159.42

* Pertains to expenses incurred towards the Scheme of arrangement and consequent listing of the Company, as referred in note 5 above. Expenses majorly includes legal and professional fees, provisional stamp duty expenses, one-time incentive and awards to employees and interest on prepayment of debt pursuant to the Scheme of arrangement.

9 Information on Standalone Financial Results from continuing operations:

Particulars	Quarter ended			Year ended	
	March 31, 2025	December 31, 2024	March 31, 2024	March 31, 2025	March 31, 2024
Total Income	4,813.23	3,426.55	757.77	13,172.71	1,761.44
Profit / (loss) before tax	1,748.77	(730.23)	(400.12)	(214.55)	(3,649.34)
Profit / (loss) after tax	1,748.77	(730.23)	(400.12)	200.00	(3,649.34)

10 Claims not acknowledged as debts by the Group

During the year ended March 31, 2023, Bioclexis Pte Limited, ('Bioclexis') subsidiary of the Company has received a claim from Prestige Biopharma Limited ('Prestige'/ 'manufacturing partner') of USD 136.32 million (Rs. 11,647.58) million towards reimbursement of expenditure claiming that it suffered loss and damage due to the Contract Manufacturing Agreement to manufacture Sputnik Light Vaccine being terminated by Bioclexis. The same has not been acknowledged as debt in the books of Group.

Further Bioclexis has counter claimed for failure to supply and breaches under the collaboration agreement towards procuring equipment and consumables, which are unusable. Bioclexis has already taken legal recourse through its external legal counsel to refute the claims that are false, baseless, and misconceived and has sought a 100% refund of the Capacity fee of USD 13.62 million (Rs.1163.73 million) which was paid to Prestige guaranteeing the prompt refund of the Capacity fee paid to Prestige in case no manufacturing occurs within the agreed timelines.

Currently, this matter is pending before Singapore International Arbitration Centre (SIAC). The Group firmly believes that the claim from Prestige has no legal merit and that claims are frivolous.

- 11 During the year ended March 31, 2025, the Company fully repaid its listed non-convertible debentures. The security against these debentures secured by a pari passu charge over certain specified movable assets, as well as an exclusive charge on specific fixed deposits with the bank are released during the quarter ended March 31, 2025.
- 12 The figures for the quarter ended March 31, 2025 are the balancing figures between audited figures in respect to full financial years and the published unaudited year to date figures upto the end of the third quarter of the relevant financial year, which are subjected to limited review.
- 13 Disclosure as per Regulation 52(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended, are provided as annexure to this Statement.

For and on behalf of Board of Directors of OneSource Specialty Pharma Limited (formerly known as Stelis Biopharma Limited)

NEERAJ SHARMA
Digitally signed
by NEERAJ SHARMA
Date: 2025.05.05
19:20:01 +05'30'

Neeraj Sharma
Managing Director
DIN : 09402652

Place : Bengaluru
Date : May 5, 2025

OneSource Specialty Pharma Limited (formerly known as Stelis Biopharma Limited)

Registered Office : Unit no. 902, " Cyber One" situated at Plot no.-4 & 6, Sector 30A, Vashi, Navi Mumbai-400703

Corporate Office : Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road, Bangalore - 560076, India

CIN: L74140MH2007PLC432497, **Website :** <https://www.onesourcecdmo.com>, **Mail:** info@onesourcecdmo.com

Additional disclosures of Consolidated Financial Results as per Regulation 52(4) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, as amended

Sl.No.	Particulars	Quarter ended			Year ended	
		March 31, 2025	December 31, 2024	March 31, 2024	March 31, 2025	March 31, 2024
1	Debt-Equity Ratio - in times (A) / (B) Debt including lease liabilities(A) Equity (B)	0.16	0.19	1.44	0.16	1.44
2	Debt Service Coverage Ratio - in times (C) / ((D) + (E)) Earnings Before Interest, Taxes, Depreciation and Amortisation (C) Debt repayment (D) Interest payments (E)	2.21	0.39	(0.00)	0.63	(0.11)
3	Interest Service Coverage Ratio (F) / (G) Earnings Before Interest and Taxes (F) Interest on borrowings (G)	4.23	2.14	(1.11)	1.52	(1.98)
4	Outstanding redeemable preference shares (quantity and value)	NA	NA	NA	NA	NA
5	Capital redemption reserve/debenture redemption reserve	NA	NA	NA	NA	NA
6	Net worth (million) (as per Section 2(57) of Companies Act,2013)	58,805.79	57,821.34	3,957.13	58,805.79	3,957.13
7	Net profit after tax	991.92	(688.49)	(401.70)	(172.81)	(3,656.97)
8	Current Ratio - in times (H) / (I) Current Assets (H) Current Liabilities (I)	0.98	0.84	0.28	0.98	0.28
9	Long term debt to working capital - in times (J) / (K) Non-current borrowings including lease liabilities (J) Working capital (Current assets - Current liabilities) (K)	(13.97)	(1.74)	(0.62)	(13.97)	(0.62)
10	Bad Debts to accounts receivable ratio (L) / (M) Bad Debts (L) Average Gross trade receivables (M)	0.00	NA	NA	0.00	NA
11	Current Liability ratio (N)/(O) Total Current liabilities (N) Total Liabilities (O)	0.67	0.71	0.69	0.67	0.69
12	Total debt to total assets ratio (P) / (Q) Total Borrowings including lease liabilities (P) Total Assets (Q)	0.12	0.14	0.44	0.12	0.44
13	Trade receivables turnover ratio (R) / (S) Revenue from operations (R) Average Trade receivables (S)	0.83	0.82	1.97	5.47	5.82
14	Inventory turnover ratio (T) / (U) Consumables (T) Average Inventory (U)	0.70	0.68	1.80	5.14	0.98
15	Operating margin % (V) / (W) Earnings before depreciation, interest, tax and exceptional items (-) Other income (V) Revenue from operations (W)	42.85%	36.14%	-3.83%	32.29%	-51.33%
16	Net profit margin % (X) / (Y) Net profit (X) Gross Revenue (Y)	23.13%	-17.24%	-53.01%	-1.18%	-207.61%

Note: The figures for the reported periods have been provided for comparison purposes.

Date: May 05, 2025

BSE Limited Listing Department- Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001 Scrip Code: 544292, ISIN: INE013P01021	National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051 Symbol: ONESOURCE
---	---

Dear Sir/ Madam,

Subject: **Declaration pursuant to Regulation 33(3)(d) of SEBI (LODR) Regulations, 2015**

In compliance with regulation 33(3)(d) of SEBI(LODR) Regulations, 2015, as amended by SEBI from time to time Circular No. CIR/CFD ICMD 156/2016 dated May 27, 2016, we hereby confirm that the Statutory Auditors of the Company, Deloitte Haskins & Sells, Chartered Accountants, (Firm's Registration No. 008072S), Bengaluru, have issued the Auditor's Report with unmodified opinion in respect to the Standalone & Consolidated Audited Financial Results of the Company for the quarter and year ended on March 31, 2025.

The above information is also available on the website of the Company i.e. <https://www.onesourcecdmo.com/investor-relations/stock-exchange-intimation/>. You are requested to kindly take the same on record.

For and on behalf of
OneSource Specialty Pharma Limited

Digitally signed by
Trisha A
Date: 2025.05.05
19:20:11 +5.30

Trisha A
Company Secretary and Compliance Officer
Membership Number: A47635

Disclosure in respect to appointment of Secretarial Auditors of the Company for a period of 5 years as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with relevant SEBI Circulars.

Sl.No	Particulars	Details
1	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment for a period of 5 (five) years as per Regulation 24A of SEBI (LODR) Regulations, 2015.
2	date of appointment/re-appointment/cessation (as applicable) & term of appointment/re-appointment	May 05,2025 Subject to approval of the shareholders in the Annual General Meeting.
3	Brief Profile	Attached as Annexure I



Profile

Established in 2020 by CS Vivek Kumar and CS Dhanya Paul, DV & Associates is a dynamic firm of Company Secretaries located in Kochi dedicated to simplifying the complexities of corporate law. With a foundation built on extensive research, we offer a comprehensive suite of services, encompassing company secretarial work, representation before statutory bodies, and robust compliance and governance solutions. Driven by the motto "Clarity with Simplicity" DV & Associates is committed to providing accessible and insightful guidance, aiming to set the standard for excellence in their practice.

Partners

CS Vivek Kumar M.Com., LL.B, FCS

CS Vivek Kumar, the Managing Partner of DV & Associates, brings a wealth of expertise to the firm, fortified by a post-graduate degree in Commerce, a law degree, and fellow membership with the ICSI. With 13 years of dedicated experience, he excels in navigating complex company law procedures, representing clients before statutory authorities, and crafting robust compliance and governance frameworks. Notably, his proven track record includes successfully steering mergers and amalgamations through the National Company Law Tribunal and executing fast-track mergers via the Regional Director, Ministry of Corporate Affairs, demonstrating a deep understanding and mastery of corporate restructuring. Moreover, he possesses a valuable and extensive expertise in FEMA procedures, as well as Arbitration and Mediation, adding further depth to his comprehensive skill set.

CS Dhanya Paul M.Com, FCS

CS Dhanya Paul, a Fellow Member of the ICSI and post-graduate in Commerce, contributes 6 years of focused expertise to DV & Associates, specializing in Company Law Procedures, compliance, and governance. Her dynamic approach particularly shines in her dedication to accelerating startup growth and navigating the complexities of SEBI compliances. With a keen understanding of the evolving business landscape, she provides invaluable guidance to clients, ensuring they thrive within the regulatory framework.

Head Office:

Door No. 52/2066, 2nd Floor, Tharayathu,
Valiyaparambil Road (Lane 14),
Janatha Road, Vyttila, Ernakulam, Kerala, India, PIN: 682019
Email: csvivekkumartg@gmail.com
Mob: +91 98477 25152
Office: +91 77362 71201

Branch Office:

Talkus Building ,
Airport Road, Angamaly South
Angamaly, Kerala ,India Pin: 683572
Email: talkuscs@gmail.com
Mobile: +91 98465 05914
Office: +91 9846505993



Our clientele, *inter alia*, includes the following esteemed organizations:

1. Supra Pacific Financial Services Limited (Listed);
2. Aster DM Healthcare Limited (Listed);
3. CML Biotech Limited (Unlisted Public Company in process of listing);
4. Crust 'N' Crumb Food Innovations Private Limited (Private Limited Company in process of listing);

Head Office:

Door No. 52/2066, 2nd Floor, Tharayathu,
Valiyaparambil Road (Lane 14),
Janatha Road, Vyttila, Ernakulam, Kerala, India, PIN: 682019
Email: csvivekkumartg@gmail.com
Mob: +91 98477 25152
Office: +91 77362 71201

Branch Office:

Talkus Building ,
Airport Road, Angamaly South
Angamaly, Kerala ,India Pin: 683572
Email: talkuscs@gmail.com
Mobile: +91 98465 05914
Office: +91 9846505993

Date: 5th May 2025

BSE Limited Listing Department- Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001 Scrip Code: 544292, ISIN: INE013P01021	National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051 Symbol: ONESOURCE
---	---

Dear Madam/ Sir,

Sub: Outcome of the Board Meeting

Ref.: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

We wish to inform you that the Board of Directors of the Company at its meeting held on May 05, 2025, has approved in-principle the consolidation of the Singapore business operations of its wholly owned subsidiary, Stelis Pte Ltd, and/or its wholly owned step-down subsidiary, Strides Softgel Pte Ltd, into another wholly owned subsidiary, Onesource Specialty Pte Ltd.

The management has engaged legal and tax advisors to assist in evaluating the consolidation structure. The Board has delegated authority to the management committee and/or the Managing Director and Chief Financial Officer to finalize and approve the consolidation structure based on internal assessment and recommendations from legal and tax advisors.

The transaction, on consummation will not have any impact on the financials of the Company on a consolidated basis as the transaction is envisaged among wholly owned subsidiaries.

Requisite details in accordance with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/0155 dated November 11, 2024 are enclosed herewith as Annexure 1.

Kindly take the above information in your records.

Thanking You.
For **OneSource Specialty Pharma Ltd,**

Trisha A
Digitally signed by Trisha A
Date: 2025.05.05
19:30:11 +5'30

Trisha A
Company Secretary
ICSI Membership No.: A47635

Encl: As above

Annexure 1

Disclosure under Regulation 30 of SEBI Listing Regulation read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/0155 dated November 11, 2024

#	Particulars
1)	Details and reasons for restructuring
	The inter-group transfer is undertaking for the following: <ol style="list-style-type: none"> 1. Streamlining business activities to drive operational efficiency and agility in decision-making and execution. 2. Reducing duplication of administrative and support functions, thereby optimizing costs across legal, finance, human resources, and compliance areas 3. Establishing a simplified business structure, ensuring greater oversight and reducing operational complexity.
2)	Quantitative and/ or qualitative effect of restructuring
	The consolidation is expected to significantly enhance operational efficiency and streamline business operations, resulting in improved resource utilization and cost optimization.
3)	Details of benefit, if any, to the promoter/ promoter group/ group companies from such proposed restructuring
	Not Applicable
4)	Brief details of change in shareholding pattern (if any) of all entities
	Not Applicable – Since the same is an internal restructuring
